End-of-Life Delirium: Issues Regarding Recognition, Optimal Management, and the Role of Sedation in the Dying Phase Shirley H. Bush, MBBS, MRCGP, FAChPM, Maeve M. Leonard, MB, MRCPsych, MD, Meera Agar, MBBS, FRACP, Juliet A. Spiller, MBChB, MRCPEd, Annmarie Hosie, RN, PhD(C), David Kenneth Wright, RN, PhD, CHPCN(C), David J. Meagher, MD, PhD, MRCPsych, David C. Currow, BMed, MPH, FRACP, Eduardo Bruera, MD, Peter G. Lawlor, MB, FRCPI, MMedSc Journal of Pain and Symptom Management Volume 48, Issue 2, Pages 215-230 (August 2014) DOI: 10.1016/j.jpainsymman.2014.05.009 Copyright © 2014 American Academy of Hospice and Palliative Medicine Terms and Conditions
Fig. 1 End-of-life delirium: framework for clinical decision-making and designation of nonreversible and refractory delirium outcomes. *Nonsedating typical or atypical antipsychotic; †add rescue dose of benzodiazepine or change to sedating antipsychotic to specifically achieve mild-to-moderate levels of sedation as a goal; ‡includes other nonpharmacologic approaches. Journal of Pain and Symptom Management 2014 48, 215-230DOI: (10.1016/j.jpainsymman.2014.05.009) Copyright © 2014 American Academy of Hospice and Palliative Medicine Terms and Conditions